New therapeutic targets for the treatment of neurodegenerative disease, diabetes mellitus, congesstive heart failure, oncologic and immunologic disease - synthesis of bulk chemicals and drugs for…
Ended Definitive Contract Awarded Last action
- Contract number
- 00260200309D260031011
- Awardee
-
Sri International UEI SRG2J1WS9X63
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $478,552
Award facts
- Contract value 477% obligated
- $100,322.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- Immediate Office of the Secretary Department of Health and Human Services
- NAICS code
- Not on record
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Menlo Park, CA 94025, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $100,322 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $97,920 | |
| Exercise an Option | $95,609 | |
| Original award | $184,701 |
About this award
This is a $100,322.00 cost-plus-fixed-fee definitive contract awarded by the Immediate Office of the Secretary, a civilian U.S. government agency, to Sri International, a non-profit research and development institute. The contract is for the synthesis of bulk chemicals and drugs for preclinical and clinical studies related to the treatment of neurodegenerative diseases, diabetes, congestive heart failure, oncologic and immunologic diseases. Sri International is not a small business, and the contract does not have a set-aside designation.
As a large non-profit organization, Sri International frequently serves as a prime contractor and subcontractor on federal research and development projects for agencies such as the Department of Defense, National Institutes of Health, National Aeronautics and Space Administration, and Department of Education. Sri International holds several indefinite delivery vehicles (IDVs) that allow government agencies to efficiently procure its scientific, engineering, and technical services across a wide range of disciplines.
Description
New therapeutic targets for the treatment of neurodegenerative disease, diabetes mellitus, congesstive heart failure, oncologic and immunologic disease - synthesis of bulk chemicals and drugs for preclinical and clinical studies
Quick answers
Who was awarded contract 00260200309D260031011?
00260200309D260031011 was awarded to Sri International by National Institute on Drug Abuse (National Institutes of Health) on September 15, 2003.
How much is contract 00260200309D260031011 worth?
The government has obligated $478,552 on 00260200309D260031011. Its current value, with exercised options, is $100,322.
Which agency awarded contract 00260200309D260031011?
National Institute on Drug Abuse (National Institutes of Health) awarded 00260200309D260031011, with funding from Immediate Office of the Secretary (Department of Health and Human Services).
Was contract 00260200309D260031011 competed?
The extent of competition for 00260200309D260031011 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award